We have located links that may give you full text access.
Reproductive toxicity of ofloxacin.
Arzneimittel-Forschung 1986 August
The reproductive toxicity of (+/-)-9-fluoro-2, 3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de] [1,4]benzoxazine-6-carboxylic acid (ofloxacin, Tarivid), a new antibacterial agent, was investigated in rats and rabbits after oral administration. Neither the male or female fertility nor the reproductive performance of the rats was affected by doses of up to 360 mg/kg. Ofloxacin elicited no evidence of teratogenicity when administered orally during the period of organogenesis to pregnant rats at doses of up to 810 mg/kg, or to pregnant rabbits at doses of up to 160 mg/kg. However, the female rats receiving 810 mg/kg showed salivation, dirty hair coats, soft stools, and decreases of body weight and food intake. The fetuses in the higher dose groups exhibited decreased body weight and retardation of ossification, and those in the highest dose group showed increased mortality and skeletal variations (cervical ribs, shortened 13th ribs). Further investigation of the fetal skeleton revealed that the critical period of the occurrence of skeletal variations was on days 9 and 10 of gestation. The occurrence of cervical ribs and shortened 13th ribs was not an indicator of teratogenicity when ofloxacin was administered at doses of up to 1600 mg/kg during the critical period. Moreover, the shortening of the 13th ribs was the only type of retardation of ossification degree. Decreases of maternal body weight and food intake, and increased mortality of fetuses were observed in rabbits at a dose of 160 mg/kg. In a perinatal and postnatal toxicity study in rats using doses of up to 360 mg/kg, no adverse effects were observed.
Full text links
Related Resources
Trending Papers
Haemodynamic monitoring during noncardiac surgery: past, present, and future.Journal of Clinical Monitoring and Computing 2024 April 31
Obesity pharmacotherapy in older adults: a narrative review of evidence.International Journal of Obesity 2024 May 7
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.Circulation 2024 May 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app